Symbols

ARDX

Ardelyx·NASDAQ

--(--)

ARDX fundamentals

ARDX Q4 2025 Earnings

Ardelyx (ARDX) released its earnings on Feb 19, 2026: revenue was 125.22M (YoY +7.82%), beat estimates; EPS was 0 (YoY -100.00%), missed estimates.

Revenue / YoY

125.22M

+7.82%

EPS / YoY

-100.00%

Report date

Feb 19, 2026

ARDX Earnings Call Summary for Q4,2025

IBSRELA Supercharge: 73% revenue growth in 2025 to $274M, with 2026 guidance of $410-430M (50%+ YoY). CIC label expansion on track for 2029 $1B target.
XPHOZAH Resilience: 9% dispense growth post-Medicare loss, non-Medicare paid dispenses up 41%. Specialty pharmacy network adoption boosts fill rates.
Pipeline Power: $71.5M R&D investment in 2025 for CIC trial and 531 development. 531 shows 10x potency, poised for Phase I in 2026.
IP Fortification: New formulation patent listed in Orange Book until 2042, supporting long-term franchise value.
Cash Clarity: $265M cash on hand, positive cash flow in last 2 quarters, with 2026 OpEx up 25% to $520M.

Earnings

EPS

Revenue

Revenue & Expenses

ARDX has released its 2025 Q4 earnings report, with revenue of 125.22M, reflecting a YoY change of 7.82%, and net profit of -407.00K, showing a YoY change of -108.76%. The Sankey diagram below clearly presents ARDX's revenue sources and cost distribution.

Key Indicators

Ardelyx (ARDX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Ardelyx (ARDX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Ardelyx (ARDX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Ardelyx (ARDX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown